Flagship-backed Evelo Biosciences joins Covid-19 hunt with proposal for bacteria trial
A Flagship-backed biotech wants to fight the microbe now ravaging much of the earth with another microbe.
Today, Evelo Biosciences announced they filed an IND to test their lead drug — a specially-grown bacteria — in Covid-19 patients. The idea is that the bacteria, originally developed to treat inflammatory disorders, will turn down the immune system in patients, potentially calming the overactive inflammatory response that doctors believe is causing the most severe symptoms in at least some patients.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,300+ biopharma pros reading Endpoints daily — and it's free.